Given the multifaceted role of STAT3 in promoting NSCLC tumorigenesis and its association with a poor prognosis in human patients, therapeutic modalities based on STAT3 inhibition will have widespread therapeutic applications. The gene discussed is STAT3; the disease is non-small cell lung carcinoma.